Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 9421

1.

Domestic versus imported drug-eluting stents for the treatment of patients with acute coronary syndrome.

Yao HM, Sun TW, Wan YD, Zhang XJ, Fu X, Shen DL, Zhang JY, Li L.

World J Emerg Med. 2014;5(3):175-81. doi: 10.5847/wjem.j.1920-8642.2014.03.003.

PMID:
25225580
[PubMed]
2.

Coronary artery bypass grafting is superior to first-generation drug-eluting stents for unprotected left main coronary artery disease: An updated meta-analysis of 4 randomized, controlled trials.

Benedetto U, Ng C, Smith R, Raja SG; Cardiac Outcomes Meta-Analysis (COMET) Group.

J Thorac Cardiovasc Surg. 2014 Aug 19. pii: S0022-5223(14)01120-9. doi: 10.1016/j.jtcvs.2014.08.028. [Epub ahead of print] No abstract available.

PMID:
25224547
[PubMed - as supplied by publisher]
3.

Causes of very late stent thrombosis investigated using optical coherence tomography.

Amioka M, Shiode N, Kawase T, Kagawa Y, Yamane K, Takahashi L, Okubo Y, Tamekiyo H, Otsuka M, Okimoto T, Masaoka Y, Hayashi Y, Itakura K, Kato M, Dote K, Kihara Y; HERO (Hiroshima Heart Study Group) Investigators.

Intern Med. 2014;53(18):2031-9. Epub 2014 Sep 15.

PMID:
25224184
[PubMed - in process]
Free Article
4.

Reduced sirolimus systemic exposure and improved bioresorbable polymer properties: new allies for the treatment of patients with coronary artery disease.

Stojkovic S, Neskovic AN, Mehmedbegovic Z, Kafedzic S, Ostojic M, Nedeljkovic M, Orlic D, Ilisic B, Ilic I, Aleksic A, Cerovic M, Nikolajevic I, Vlahovic-Stipac A, Stajic Z, Putnikovic B, Hamilos M.

Fundam Clin Pharmacol. 2014 Sep 16. doi: 10.1111/fcp.12092. [Epub ahead of print]

PMID:
25223651
[PubMed - as supplied by publisher]
5.

In Vitro Evaluation of Cenderitide-Eluting Stent I -An Antirestenosis and Proendothelization Approach.

Ng XW, Huang Y, Liu KL, Lim SG, Chen HH, Burnett JC Jr, Freddy Boey YC, Venkatraman SS.

J Pharm Sci. 2014 Sep 15. doi: 10.1002/jps.24165. [Epub ahead of print]

PMID:
25223419
[PubMed - as supplied by publisher]
6.

Three-Year Patient-Related and Stent-Related Outcomes of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World Practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).

Lee JM, Park KW, Han JK, Yang HM, Kang HJ, Koo BK, Bae JW, Woo SI, Park JS, Jin DK, Jeon DW, Oh SK, Park JS, Kim DI, Hyon MS, Jeon HK, Lim DS, Kim MG, Rha SW, Her SH, Hwang JY, Kim S, Choi YJ, Kang JH, Moon KW, Jang Y, Kim HS.

Am J Cardiol. 2014 Aug 12. pii: S0002-9149(14)01586-0. doi: 10.1016/j.amjcard.2014.07.065. [Epub ahead of print]

PMID:
25217457
[PubMed - as supplied by publisher]
7.

Advances in percutaneous coronary interventions for elderly patients.

Brenes-Salazar JA, Forman DE.

Prog Cardiovasc Dis. 2014 Sep-Oct;57(2):176-86. doi: 10.1016/j.pcad.2014.07.002. Epub 2014 Jul 7.

PMID:
25216617
[PubMed - in process]
8.

Promoting endothelial recovery and reducing neointimal hyperplasia using sequential-like release of acetylsalicylic acid and paclitaxel-loaded biodegradable stents.

Lee CH, Yu CY, Chang SH, Hung KC, Liu SJ, Wang CJ, Hsu MY, Hsieh IC, Chen WJ, Ko YS, Wen MS.

Int J Nanomedicine. 2014 Aug 27;9:4117-33. doi: 10.2147/IJN.S67721. eCollection 2014.

PMID:
25206303
[PubMed - in process]
Free PMC Article
9.

Effect of Angiotensin Converting Enzyme Inhibitors on Soluble Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand Levels - Association With Neointimal Hyperplasia in Drug Eluting Stents.

Giannopoulos G, Panagopoulou V, Deftereos S, Angelidis C, Davlouros P, Synetos A, Toutouzas K, Alexopoulos D, Cleman MW, Tousoulis D.

J Interv Cardiol. 2014 Sep 9. doi: 10.1111/joic.12153. [Epub ahead of print]

PMID:
25203156
[PubMed - as supplied by publisher]
10.

Biodegradable polymer brush as nanocoupled interface for improving the durability of polymer coating on metal surface.

Bedair TM, Cho Y, Joung YK, Han DK.

Colloids Surf B Biointerfaces. 2014 Aug 27. pii: S0927-7765(14)00448-2. doi: 10.1016/j.colsurfb.2014.08.025. [Epub ahead of print]

PMID:
25200098
[PubMed - as supplied by publisher]
11.

Clinical outcomes in the percutaneous coronary intervention of in-stent restenosis with everolimus-eluting stents.

Lee MS, Yang T, Mahmud E, Park KW, Kim HS, Kim MH, Dangas G, Hermiller J, Krucoff M, Rutledge D.

J Invasive Cardiol. 2014 Sep;26(9):420-6.

PMID:
25198484
[PubMed - in process]
Free Article
12.

A Randomized Comparison Study Assessing the Impact of Cilostazol on the Heart Rate and Arrhythmias by 24-Hour Ambulatory Holter Electrocardiographic Monitoring after Drug-Eluting Stent Implantation for Coronary Artery Disease.

Kwon BJ, Lee SH, Kim DB, Park HJ, Jang SW, Ihm SH, Kim HY, Seung KB.

J Atheroscler Thromb. 2014 Sep 8. [Epub ahead of print]

PMID:
25195813
[PubMed - as supplied by publisher]
Free Article
13.

Long-term clinical outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease.

Higami H, Shiomi H, Niki S, Tazaki J, Imai M, Saito N, Makiyama T, Shizuta S, Shioi T, Ono K, Kimura T.

Cardiovasc Interv Ther. 2014 Sep 7. [Epub ahead of print]

PMID:
25194953
[PubMed - as supplied by publisher]
14.

Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.

Pilgrim T, Heg D, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Fahrni T, Moschovitis A, Noble S, Eberli FR, Wenaweser P, Jüni P, Windecker S.

Lancet. 2014 Aug 29. pii: S0140-6736(14)61038-2. doi: 10.1016/S0140-6736(14)61038-2. [Epub ahead of print]

PMID:
25189359
[PubMed - as supplied by publisher]
15.

Improved Adverse Postoperative Outcomes With Revised American College of Cardiology/American Heart Association Guidelines for Patients With Cardiac Stents.

Graham LA, Singletary BA, Richman JS, Maddox TM, Itani KM, Hawn MT.

JAMA Surg. 2014 Sep 3. doi: 10.1001/jamasurg.2014.2044. [Epub ahead of print]

PMID:
25188466
[PubMed - as supplied by publisher]
16.

Meta-analysis of three randomized controlled trials comparing coronary artery bypass grafting with percutaneous coronary intervention using drug-eluting stenting in patients with diabetes.

Fanari Z, Weiss SA, Zhang W, Sonnad SS, Weintraub WS.

Interact Cardiovasc Thorac Surg. 2014 Sep 3. pii: ivu291. [Epub ahead of print]

PMID:
25185569
[PubMed - as supplied by publisher]
Free Article
17.

The impact of renal impairment on long-term safety and effectiveness of drug-eluting stents.

Stefanini GG, Taniwaki M, Kalesan B, Räber L, Stortecky S, Pilgrim T, Onuma Y, Silber S, Serruys PW, Meier B, Jüni P, Windecker S.

PLoS One. 2014 Sep 3;9(9):e106450. doi: 10.1371/journal.pone.0106450. eCollection 2014.

PMID:
25184244
[PubMed - in process]
Free PMC Article
18.

Preoperative management of antiplatelet drugs for a coronary artery stent: how can we hit a moving target?

Vetter TR, Hunter JM Jr, Boudreaux AM.

BMC Anesthesiol. 2014 Aug 23;14:73. doi: 10.1186/1471-2253-14-73. eCollection 2014.

PMID:
25183953
[PubMed - in process]
Free PMC Article
19.

Cobalt-Chromium KAname™ coRonary stEnt System in the Treatment of Patients With Coronary Artery Disease (KARE Study).

Carrie D, Schächinger V, Danzi GB, Macaya C, Zeymer U, Putnikovic B, Iniguez A, Moreno R, Mehmedbegovic Z, Beleslin B; ON BEHALF OF KARE INVESTIGATORS.

J Interv Cardiol. 2014 Aug 30. doi: 10.1111/joic.12144. [Epub ahead of print]

PMID:
25175153
[PubMed - as supplied by publisher]
20.

Recent Developments in Drug-eluting Coronary Stents.

Yildiz M, Yildiz B, Gursoy MO, Akin I.

Cardiovasc Hematol Disord Drug Targets. 2014 Aug 23. [Epub ahead of print]

PMID:
25174714
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk